Press Releases Year None2020201920182017 Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models Jun 22, 2020 Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare Conference Webcast Jun 01, 2020 Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046 May 29, 2020 Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock May 27, 2020 Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock May 18, 2020 Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock May 18, 2020 Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response May 12, 2020 Turning Point Therapeutics to Host First Quarter Conference Call May 04, 2020 Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib in Treatment-Naïve and Solvent-Front Mutation Ros1-Positive Non-Small Cell Lung Cancer Apr 16, 2020 TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS Mar 16, 2020 Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18
Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models Jun 22, 2020
Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare Conference Webcast Jun 01, 2020
Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046 May 29, 2020
Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock May 27, 2020
Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock May 18, 2020
Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response May 12, 2020
Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib in Treatment-Naïve and Solvent-Front Mutation Ros1-Positive Non-Small Cell Lung Cancer Apr 16, 2020
TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS Mar 16, 2020
